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Abstract: Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous 
group of peripheral T-cell lymphomas, which is characterized by large pleomorphic cells with 
strong expression of CD30. Translocations involving ALK, the anaplastic lymphoma kinase 
gene, are associated with a favorable clinical outcome. Such ALK-positive ALCLs are usually 
responsive to a multidrug chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincris-
tine, prednisone). However, there is no general consensus on the optimal therapy for relapsed 
or refractory ALCL. We report the case of a 24-year-old male suffering from ALK-positive 
ALCL with an uncommon manifestation of only extranodal disease in the gastric cardia region 
that showed primary refractoriness to standard CHOP chemotherapy. A combination therapy 
consisting of the anti-CD30 drug conjugate, brentuximab vedotin, and classical lymphoma 
salvage regimen DHAP (cisplatin, high-dose cytarabine and dexamethasone) was administered. 
Following two treatment cycles in 21-day intervals, the lymphoma showed considerable regres-
sion based on imaging diagnostics and no evidence of vital lymphoma in a subsequent biopsy. 
We did not observe any increase in toxicity; in particular, polyneuropathy and febrile neutro-
penia were not observed. In summary, we report that the antibody-drug conjugate brentuximab 
vedotin and a classical regimen used for aggressive lymphoma, DHAP, could be combined as 
salvage therapy in a case of refractory ALK-positive ALCL. Phase I/II studies will be required 
for safety and efficacy analysis.
Keywords: anaplastic large cell lymphoma (ALCL), refractory/relapsed lymphoma, anti-CD30 
drug conjugate, DHAP, combined therapy
Introduction
The primary systemic type of anaplastic large cell lymphoma (ALCL) is a common 
subtype of the heterogeneous group of peripheral T-cell lymphomas (PTCL). PTCL 
together account for less than 15% of all non-Hodgkin lymphomas in adults.1 The 
ALK-positive subtype of ALCLs is defined by different translocations involving 
the anaplastic lymphoma kinase (ALK) gene on chromosome 2 that result in an 
overexpression of a constitutively active kinase. Such ALK-positive ALCLs proved 
to have a more favorable outcome compared to ALK-negative lymphomas.2 ALCLs 
show bimodal age distribution, peaking in early and late adulthood, with the median 
age at the time of diagnosis being much lower in patients with ALK-positive ALCL 
(34 years versus 58 years in ALK-negative ALCL).3 Patients typically present with 
painless lymphadenopathy with concomitant B-symptoms. Extranodal disease 
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manifestations are most common in skin, bone, lung, and 
liver. The neoplastic cells characteristically show strong 
expression of CD30 and cytotoxicity-associated anti-
gens, while the expression of pan-T-cell antigens is often 
lost.4 Clinically, ALK-positive ALCLs typically show an 
aggressive course but are usually responsive to standard 
CHOP or CHOP-like therapy, with the most important 
prognostic factor being the International Prognostic Index 
(IPI) at the time of diagnosis.2 However, there is no general 
consensus on the optimal therapy for relapsed or refrac-
tory ALCL.5 Here, we report on a combination therapy 
with cisplatin, high-dose cytarabine, and dexamethasone 
(DHAP) and brentuximab vedotin, a CD30-directed 
antibody linked to the antitubulin agent monomethyl 
auristatin E,6,7 in a young patient with primarily refractory 
ALK-positive ALCL.
Case presentation
A 24-year-old male was admitted to a primary care hospital 
because of persistent dyspepsia, epigastric pain, and weight 
loss. A gastroscopy revealed an exophytic, ulcerating tumor 
in the cardia region and proximal corpus of the stomach 
with extension into the distal esophagus. Mucosal biopsies 
showed infiltration by an ALK-positive, CD20-negative 
large cell lymphoma accompanied by chronic Helicobacter 
pylori-negative antrum gastritis. A subsequent computed 
tomography (CT) scan and bone marrow biopsy showed 
exclusive involvement of the stomach. The IPI score was 0. 
Standard chemotherapy with CHOP was initiated. Under 
such anthracycline-based chemotherapy, patients with ALK-
positive ALCL generally show a favorable outcome with a 
5-year overall survival ranging from 70% to 93%.8,9 In this 
particular case, following three cycles of the CHOP regi-
men, a CT scan demonstrated partial remission. However, 
following cycle five, a CT scan of the chest and upper abdo-
men was performed because of productive coughing, which 
showed local tumor progression. The CHOP regimen was 
discontinued and the patient was subsequently transferred 
to our hospital.
On admission the patient presented in good general 
condition but was suffering from worsening dyspepsia, 
shoulder pain, and night sweats. Physical examination was 
unremarkable; blood count and laboratory values were – 
apart from mild anemia (hemoglobin 13.7 g/dL) – within 
normal limits. [18F]Fluorodeoxyglucose positron emis-
sion tomography (PET)-CT revealed intensive tracer 
uptake by the known lymphoma manifestation in the 
cardia region, with a tumor size of 60 × 60 × 65 mm. 
Two additional nodules cranial to the primary tumor with 
enhanced glucose uptake were considered as affected 
lymph nodes (Figure 1A). Other manifestations were not 
identified. A second endoscopic mucosal biopsy showed 
infiltration by highly-proliferating lymphoid cells, staining 
positive for CD30 and CD3 with nuclear and cytoplasmic 
expression of ALK and negativity for CD19, CD79a, and 
CD38 (Figure 2), again showing ALK-positive large cell 
lymphoma, Ann Arbor stage IIE, age-adjusted IPI low 
risk. Based on the immunohistochemical features and the 
refractoriness to CHOP, ALK-positive large B-cell lym-
phoma (LBCL), which is usually characterized by CD20 
negativity and sometimes stains positive for CD30,10 was 
also considered, and the biopsy was sent to a national 
reference center for hematopathology.
Considering the primary refractoriness towards standard 
CHOP treatment and the possibility of ALK-positive LBCL, 
which is associated with a poor prognosis,10 we discussed with 
the patient an individual treatment plan, consisting of the anti-
CD30 drug conjugate, brentuximab vedotin and the classical 
lymphoma salvage regimen DHAP11 (brentuximab vedotin 
1.2 mg/kg [day 0], cisplatin 70 mg/m² [day 1] over a period of 
22 hours, cytarabine [2 × 2,000 mg/m² on day 2] and dexame-
thasone [40 mg on days 2–5]) (Figure 3).  Standard supportive 
care was administered. For primary prophylaxis of prolonged 
neutropenia, pegfilgrastim 6 mg was administered on day 4. 
Because of the experimental chemotherapeutic design, dos-
ing of the first cycle was reduced to 75%. The treatment was 
very well tolerated by the patient. Erosion bleedings related 
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Figure 1 FDG-peT/CT images before and after chemotherapy with BV-DHap.
Notes: (A) FDG-peT/CT performed as restaging prior to salvage chemotherapy 
shows massively enhanced glucose uptake by the known lymphoma in the cardia 
region of the stomach (black arrows). Two additional nodules cranial to the primary 
tumor with enhanced glucose utilization were considered as affected lymph nodes 
(grey arrow). (B) FDG-peT/CT images obtained after two cycles of the BV-DHap 
regimen showed tumor regress, while a discrete lesion with enhanced glucose 
metabolism remained detectable (white arrow).
Abbreviations: BV-DHap, brentuximab vedotin and cisplatin/cytarabine; CT, com-
puted tomography; FDG, fludeoxyglucose; PET, positron emission tomography.
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to tumor lysis were not observed. The shoulder pain and night 
sweats rapidly improved under therapy. Leukapheresis for 
autologous peripheral blood stem cells was performed fol-
lowing cycle one. A short-term interim staging by CT scan 
showed partial tumor  regression.  Reference pathology finally 
confirmed the diagnosis of ALCL against ALK-positive LBCL 
(Figure 2). The second cycle brentuximab vedotin/DHAP was 
administered without complications with 100% dose levels as 
stated above. The patient denied sensory or motor polyneu-
ropathy; focal neurological deficiencies were not observed. 
Serum analysis showed normal liver and renal function tests. 
On the scale for Common Terminology  Criteria for Adverse 
Events (CTCAE), hematological toxicity was limited to the 
expected grade 2–3 neutropenia and thrombocytopenia. 
No infections occurred during the course of chemotherapy. 
A second PET-CT scan after cycle two showed further tumor 
regression, both morphologically and with regards to glu-
cose uptake (Figure 1B). A discrete swelling of the gastric 
wall with enhanced glucose metabolism remained. Biopsy 
and immunohistological analysis revealed inflammation 
without evidence of  lymphoma. The presumably affected 
lymph nodes cranial to the primary tumor were no longer 
detectable. There was no evidence of any new lesions. The 
treatment response was considered as complete remission. 
Three weeks later, the treatment was continued with consoli-
dation high-dose chemotherapy using the BEAM protocol 
(bis-chloroethylnitrosourea [BCNU], etoposide, AraC, 
melphalan)12 and autologous peripheral blood hematopoietic 
stem cell transplantation (HSCT).  Considering the primary 
refractoriness to CHOP and stage II disease, consolidat-
ing involved-field radiotherapy was applied. At the time of 
submission of this manuscript, the patient had just finished 
radiotherapy and was doing very well without any clinical 
signs of relapse.
Discussion
There is no general consensus regarding the optimal treat-
ment regimen in patients with refractory or relapsed PTCL. 
Such patients are generally treated with combination che-
motherapy regimens in an attempt to achieve a remission, 
followed by consolidating high dose chemotherapy and 
autologous HSCT, or allogeneic HSCT in medically fit 
 individuals.  Consolidation therapy with autologous HSCT 
is a highly promising option only in patients with ALK-
positive ALCL,13,14 with a complete remission at the time 
of transplantation and lack of extranodal disease being 
important predictors for a favorable outcome.15 Recently, 
novel agents for the treatment of refractory or relapsed PTCL 
have emerged, such as brentuximab vedotin, an anti-CD30 
antibody-drug conjugate. In a Phase I clinical trial involving 
45 patients with relapsed or refractory CD30+ hematopoietic 
HE CD30 ALK1
PerforinCD5CD3
Figure 2 Histopathology of the biopsied gastric mucosa.
Notes: Hematoxylin and eosin (He) staining and immunohistochemistry using the 
indicated antibodies. The large tumor cells stain positive for CD30, the cytotoxic 
marker perforin, aLK, and CD3 while CD5 remains negative.
Abbreviation: aLK, anaplastic lymphoma kinase.
d0: Brentuximab vedotin 1.2 mg/kg
      30 min iv bolus
d1: Cisplatin 70 mg/m2
     
  
continious iv infusion over 22 h
d2: Cytarabine 2 x 2,000 mg/m2
       2 x 1 h iv infusion, 12 h apart  
d22: Repeat cycle 
d4: Pegfilgrastim 6 mg sc
d2–5: Dexamethasone 40 mg po
Figure 3 schematic overview of the timing and dosing of the BV-DHap regimen. 
Notes: Dosage in cycle 1 was reduced to 75%. Cycle 2 was administered at 100% as indicated.
Abbreviations: BV-DHap, brentuximab vedotin and cisplatin/cytarabine; d, day; iv, intravenous; po, per os; sc, subcutaneous.
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neoplasms that were treated with brentuximab vedotin, 
17 patients showed an objective response, and stable disease 
was reported in 19 patients.16 In a Phase II multicenter study, 
58 patients with relapsed or refractory ALCL were treated 
with brentuximab vedotin (1.8 mg/kg every 3 weeks for up 
to 16 cycles). The overall response rate was 86% with an 
updated median progression-free survival of 14.6 months.17,18 
As reported previously, most common adverse events were 
peripheral sensory neuropathy, nausea, fatigue, pyrexia, 
diarrhea, rash, constipation, and neutropenia. On the basis 
of these data, brentuximab vedotin was approved by the 
US Food and Drug Administration and the European Medi-
cines Agency for monotherapy of ALCL after failure of at 
least one prior multiagent chemotherapy regimen. For a 
more detailed discussion of the most recent clinical stud-
ies on brentuximab vedotin in the treatment of ALCL and 
Hodgkin lymphoma, we refer to a recent review by Chen 
et al.5  Preliminary studies also showed effectiveness of bren-
tuximab vedotin in CD30+ non-ALCL PTCL.5,19,20  Numerous 
clinical trials are now ongoing to evaluate the clinical benefit 
of combination of brentuximab vedotin with classical che-
motherapy agents. Table 1 gives an overview on already 
active trials that investigate the combination of brentuximab 
vedotin and chemotherapy in adult patients with CD30+ 
ALCL or Hodgkin lymphoma. First studies have proven 
the feasibility of such an approach in patients with Hodgkin 
lymphoma.21–23 Preliminary data from an ongoing Phase 
I clinical study showed substantial antitumor activity and 
Table 1 Overview of active clinical trials that investigate brentuximab vedotin in combination with chemotherapy in adult patients with 
aLCL or Hodgkin lymphoma
Clinical trial ID Entity Status Combination therapy Phase
NCT01771107 stage III–IV HIV-associated HL Untreated aVD phase I/II
NCT01534078 Limited-stage HL Untreated aVD phase II
NCT01657331 HL or aLCL relapsed or refractory Bendamustine phase I/II
NCT01950364 HL or aLCL relapsed or refractory rifampicin phase I
NCT01780662 HL relapsed or refractory Gemcitabine phase I/II
NCT01979536 stage III–IV aLCL Untreated DXM, IFF, MTX, araC, 
Vp-16, CTX, aDr
phase II
NCT01902160 HL relapsed or refractory Temsirolimus phase I
NCT01874054 HL relapsed or refractory Bendamustine phase I/II
NCT01578967 stage I–II HL Untreated aBVD phase II
NCT01868451 stage I–II HL Untreated aBVD + 30 Gy IsrT phase II
NCT01476410 stage II–IV HL Untreated aVD phase II
NCT01712490 HL Untreated aVD phase III
NCT01777152 aLCL Untreated CHp phase III
NCT01569204 HL Untreated eCapp/eCaDD phase II
Abbreviations: aBVD, doxorubicin, bleomycin, vinblastine, dacarbazine; aDr, doxorubicin; aLCL, anaplastic large cell lymphoma; araC, cytarabine; aVD, doxorubicin, 
vinblastine, dacarbazine; CHp, cyclophosphamide, doxorubicin, and prednisone; CTX, cyclophosphamide; DXM, dexamethasone; eCaDD, etoposide, cyclophosphamide, 
doxorubicin, dexamethasone, dacarbazine; ECAPP, etoposide, cyclophosphamide, doxorubicin, prednisone, procarbazine; HIV, human immunodeficiency virus; HL, Hodgkin 
lymphoma; IFF, ifosfamide; IsrT, involved-site radiation therapy; MTX, methotrexate; Vp-16, etoposide.
manageable toxicity with the combination of brentuximab 
vedotin and CHP (CHOP without vincristine) in patients 
with newly-diagnosed ALCL or other CD30+ mature T-cell/
natural killer-cell lymphomas.24
Here, we report that the antibody-drug conjugate 
brentuximab vedotin and a multidrug chemotherapy regimen 
used for the treatment of aggressive lymphoma, DHAP, can 
be efficiently and safely combined as salvage treatment prior 
to autologous stem cell transplantation in a case of refractory 
ALK-positive ALCL. We did not observe an overt increase 
in toxicity; in particular, polyneuropathy and febrile neu-
tropenia were not observed. Because of the experimental 
character of this treatment, brentuximab vedotin has been 
limited to 1.2 mg/kg. Such combination therapy might 
improve the outcome in patients with ALK-positive ALCL 
that do not meet favorable prerequisites for consolidating 
autologous HSCT. Furthermore, in some cases, the differ-
entiation of ALCL from the anaplastic type diffuse LBCL 
or other lymphoid neoplasms of T or null cell origin can be 
challenging. In patients with arguable histological findings 
and thus uncertain prognosis, a monotherapy with brentux-
imab vedotin seems not sufficient, and such patients might 
benefit from the combination of a multiagent chemotherapy. 
In consideration of the encouraging data from preliminary 
studies of combination therapies, an individual treatment 
plan in such patients could be considered. In general, 
combined therapy with the anti-CD30 drug conjugate bren-
tuximab vedotin with a classical chemotherapy  backbone 
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may be a promising approach in the future treatment of 
CD30-expressing lymphomas. Phase I/II trials for safety 
and efficacy assessment will be required.
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